Friday, May 27, 2022 1:26:53 PM
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date/Short Interest/Percent Change/
Average Daily Share Volume/Days to Cover
05/13/2022 4,489,190 16.44 874,561 5.13
04/29/2022 3,855,387 4.25 963,159 4.00
04/14/2022 3,698,369 3.82 784,592 4.71
03/31/2022 3,562,356 (20.18) 1,276,819 2.79
03/15/2022 4,463,076 2.49 780,466 5.72
02/28/2022 4,354,553 5.05 1,141,138 3.82
02/15/2022 4,145,163 (4.26) 1,128,714 3.67
01/31/2022 4,329,470 18.97 1,517,532 2.85
01/14/2022 3,639,034 (0.65) 1,122,353 3.24
12/31/2021 3,662,710 (11.90) 752,924 4.86
12/15/2021 4,157,631 (15.83) 1,013,911 4.10
11/30/2021 4,939,519 3.29 626,906 7.88
11/15/2021 4,782,042 (3.95) 682,478 7.01
10/29/2021 4,978,819 4.72 563,617 8.83
10/15/2021 4,754,337 (6.31) 463,906 10.25
09/30/2021 5,074,576 (13.43) 622,927 8.15
09/15/2021 5,861,734 (7.98) 702,044 8.35
08/31/2021 6,369,946 (13.65) 700,582 9.09
08/13/2021 7,377,030 (9.09) 577,268 12.78
07/30/2021 8,114,425 2.81 583,170 13.91
07/15/2021 7,892,883 (3.03) 678,849 11.63
06/30/2021 8,139,602 (17.77) 1,344,492 6.05
06/15/2021 9,898,014 (2.47) 995,026 9.95
05/28/2021 10,148,533 (5.75) 982,073 10.33
05/14/2021 10,768,141 1.68 830,745 12.96
04/30/2021 10,590,475 (4.60) 774,264 13.68
04/15/2021 11,101,318 10.45 743,411 14.93
Recent VKTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 08:48:01 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 • PR Newswire (US) • 05/05/2026 11:05:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 06:21:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/30/2026 01:50:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 08:05:17 PM
- Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/29/2026 08:05:00 PM
- Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 • PR Newswire (US) • 04/22/2026 08:35:00 PM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 04/10/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:15:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:14:56 PM
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 • PR Newswire (US) • 03/26/2026 11:05:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 03/05/2026 09:03:00 PM
- Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market • PR Newswire (US) • 02/13/2026 04:26:00 PM
- Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market • PR Newswire (Canada) • 02/13/2026 04:26:00 PM
- Viking Therapeutics jumps nearly 12% on plans to move oral obesity drug into Phase 3 • IH Market News • 02/12/2026 02:48:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 10:25:49 PM
- Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/11/2026 09:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:06:25 PM
- Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 • PR Newswire (US) • 02/04/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:57:19 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:55:53 AM
- Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity • PR Newswire (US) • 01/12/2026 12:00:00 PM
